Expired Australian patentAustralia
Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer
AU 2012100098 · Applicant: Astrazeneca Ab
Overview
Drawings and full text
Its specification, documents and status are on IP Australia's AusPat.
Open the AusPat recordRead the whole patent
Listed from its IP Australia record in Patent Yard's archive of Australian patents past their term. Its claims, description and drawings are in the AusPat record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 30, 2012. An Australian innovation patent lasts at most 8 years from its date of patent, at most a year after this filing, so it ended by January 30, 2021.
- We check Australian rights only. A patent in its family in another country could still be in force.
FiledJanuary 30, 2012
GrantedFebruary 16, 2012
Term ended byJanuary 30, 2021
Application numberAU 2012100098
Classification (IPC)A61K31/565 +1 more
Timeline
Timeline From IP Australia dates
Sources & verification
Official IP Australia records
Everything on this page comes from the IP Australia record linked above. Data from IP Australia's IPGOD, licensed under CC BY 2.5 AU.